Upon sacrifice, fresh tumors were collected, homogenized using collagenase, immunostained with F4/80 and Tie2 receptor antibodies and subjected to flow cytometry for the percent of total F4/80+ cells and percent of F4/80+/Tie2+ TEMs relative to tumor cells. The gene discussed is TEK; the disease is neoplasm.